

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |  |   |
|--|--|---|
| 1. Name and Address of Reporting Person*<br><u>Mosbrooker Eric</u><br><br>(Last) (First) (Middle)<br><u>C/O AUDENTES THERAPEUTICS, INC.</u><br><u>600 CALIFORNIA STREET, 17TH FLOOR</u><br><br>(Street)<br><u>SAN FRANCISCO CA 94108</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Audentes Therapeutics, Inc. [ BOLD ]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><br>Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><u>SVP, Chief Commercial Officer</u> |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>01/03/2019</u>                      |   |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)   |  |   |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price  |   |  |   |
| Common Stock                    | 01/03/2018                           |  | A                              |   | 31,500 <sup>(1)</sup>   | A          | \$0.00 | 31,800  | D  |   |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |       |
|--|--|--------------------------------------|--|--------------------------------|--|--|-----------------|---|--|--|---|--|-------|
|  |  |                                      |  |                                |  | Date Exercisable   | Expiration Date |   |  |  |   |  | Title |
| Stock Option (right to buy)                | \$22.01  | 01/03/2019                           |  | A                              | 87,750   | (2)  | 01/03/2029      | Common Stock  | 87,750                                     | \$0.00   | 87,750  | D  |       |

**Explanation of Responses:**

- The reported transaction involved the reporting person's receipt of a grant of 31,500 restricted stock units ("RSUs") pursuant to the issuer's 2018 Equity Inducement Plan. Each RSU represents a contingent right to receive one (1) share of the issuer's common stock upon settlement for no consideration. The RSUs will vest as to 25% of the total shares on January 3, 2020, and an additional 6.25% of the total shares will vest quarterly thereafter on March 5, June 5, September 5 and December 5, with 100% of the total shares vested and exercisable on December 5, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
- The option will vest as to 25% of the total shares on January 3, 2020, and an additional 2.0833% of the total shares will vest monthly thereafter beginning February 3, 2020, with 100% of the total shares vested and exercisable on January 3, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

**Remarks:**

/s/ Thomas Soloway as  
attorney-in-fact for Eric 01/04/2019  
Mosbrooker

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.